Pharmacokinetics of teceleukin (recombinant human interleukin-2) after intravenous or subcutaneous administration to patients with cancer.

摘要: Single doses of teceleukin ranging from 0.1 to 30 x 10(6) units were administered cancer patients as intravenous infusions or subcutaneous injections. Serum samples analyzed using a bioassay. In general, was rapidly eliminated after administration, with half-lives 0.24 3.3 h. Teceleukin disappeared serum more slowly following 2.7 12.2 This finding may be result slow absorption the injection site. concentrations increased in an apparently dose-proportional manner administration. When subcutaneously, increasing dose but that less than dose-proportional, possibly due dose-dependent bioavailability for subcutaneously teceleukin.